Skip to main content

Hematopoietic Stem/Progenitor Cell Enumeration in Apheresis Collections Using a New Microfluidic Cartridge-Based Flow Cytometry Platform

Automating flow cytometric analysis enables all levels of technicians to generate accurate and precise cell enumeration and phenotyping results in real time, providing actionable in-process information.

Hematopoietic Stem/Progenitor Cell Enumeration in Apheresis Collections

Filename
Accellix-2025-ISCT-HSC-Enumeration-Mount-Sinai-Poster.pdf
Size
1 MB
Format
application/pdf

Summary

  • A new method for CD34+ cells phenotyping and enumeration in fresh HPC, A samples is in advanced stages of evaluation using the Accellix Automated Microfluidic-Based Flow Cytometry platform.
  • New gating strategy, methods of analysis and reportables have been established in line with current clinical standards.
  • Method comparison between the Accellix and predicate flow cytometry platforms demonstrate:
  • Comparable measurements of cell viability for both CD45+ and CD34+ cells.
  • Nearly identical frequencies of viable CD34+ cells showing strong correlations and concordance.
  • No significant difference and strong correlations between the absolute numbers of viable CD34+ cells.
  • Acceptable linearity in HPC, A serial dilutions and CD34+ cells spiking assays; reproducibility and inter-operator variation had a coefficient of variation of ≤10% [(n=10), data not shown].
  • Manual and automated analyses of the results obtained on the Accellix platform are comparable thus warranting transition to method validation and implementation.
  • Preliminary results indicate feasibility and accuracy of Accellix method for dual CD34+/CD3+ phenotyping and enumeration in a single assay (data not shown).

FEATURED SOLUTION

ACCELLIX™

The ACCELLIX™ Automated Cell Phenotyping Platform eliminates these limitations and automates your entire testing workflow, from sample preparation to data analysis, generating rapid cell phenotyping results directly in the collection site and/or manufacturing suite.

ACCELLIX™

Want To Discuss Your Needs? 

Complete the form below to get in touch with our team. A bioMérieux expert will be in touch using the contact information you provide. By providing your information, you agree to receive additional emails from bioMérieux about cell and gene therapy quality control.

To find out more about the management of your personal data and to exercise your rights, see our privacy policy.